Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Nature Reviews Clinical Oncology, Published online: 05 August 2020; doi:10.1038/s41571-020-0413-zThe efficacy of chemotherapy in patients with cancer is now known to have an immunogenic component. Nonetheless, chemotherapy alone often fails to provide durable disease remission in most patients. The development of immune checkpoint inhibitors has created an opportunity to combine immunogenic chemotherapies with these agents in order to optimize patient outcomes. In this Review, the authors describe the mechanisms of synergy between chemotherapy and immune checkpoint inhibitors, summarize the available clinical data on these...
Source: Nature Reviews Clinical Oncology - August 5, 2020 Category: Cancer & Oncology Authors: Lorenzo Galluzzi Juliette Humeau Aitziber Buqu é Laurence Zitvogel Guido Kroemer Source Type: research

ROS1-dependent cancers — biology, diagnostics and therapeutics
Nature Reviews Clinical Oncology, Published online: 05 August 2020; doi:10.1038/s41571-020-0408-9ROS1 fusions can be identified across a range of malignancies and confer a high level of sensitivity to ROS1 tyrosine kinase inhibitors. Herein, the authors discuss the non-malignant and malignant biology of ROS1, the diagnostic approaches to identifying ROS1 fusions and the current therapeutic concepts relating to ROS1 fusion-positive cancers, including the resistance mechanisms that have emerged with current ROS1 inhibitors. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 5, 2020 Category: Cancer & Oncology Authors: Alexander Drilon Chelsea Jenkins Sudarshan Iyer Adam Schoenfeld Clare Keddy Monika A. Davare Source Type: research

CAR T cells are active in Hodgkin lymphoma
Nature Reviews Clinical Oncology, Published online: 04 August 2020; doi:10.1038/s41571-020-0425-8CAR T cells are active in Hodgkin lymphoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 4, 2020 Category: Cancer & Oncology Authors: David Killock Source Type: research

Chemoradiotherapy improves NPC outcomes
Nature Reviews Clinical Oncology, Published online: 03 August 2020; doi:10.1038/s41571-020-0424-9Chemoradiotherapy improves NPC outcomes (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 3, 2020 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Methylation extends the reach of liquid biopsy in cancer detection
Nature Reviews Clinical Oncology, Published online: 30 July 2020; doi:10.1038/s41571-020-0420-0Measuring the methylation status of cell-free DNA (cfDNA) in plasma holds great potential for the early, noninvasive detection of cancer. Two recent papers published in Nature Medicine showcase the successful application of cfDNA methylation-based cancer detection to two highly challenging scenarios. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 30, 2020 Category: Cancer & Oncology Authors: Wenyuan Li Xianghong Jasmine Zhou Source Type: research

Proteogenomics reveals molecular subtypes
Nature Reviews Clinical Oncology, Published online: 27 July 2020; doi:10.1038/s41571-020-0419-6Proteogenomics reveals molecular subtypes (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 27, 2020 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Myocardial infarction promotes breast cancer recurrence
Nature Reviews Clinical Oncology, Published online: 24 July 2020; doi:10.1038/s41571-020-0418-7Myocardial infarction promotes breast cancer recurrence (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 24, 2020 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

TGFβ biology in cancer progression and immunotherapy
Nature Reviews Clinical Oncology, Published online: 24 July 2020; doi:10.1038/s41571-020-0403-1TGFβ released by cancer cells and other cells in the tumour microenvironment enables cancer cell invasion and dissemination, stem cell properties and therapeutic resistance as well as generating an immunosuppressive environment. The authors of this Review introduce the mechanisms underlying TGFβ signalling in tumours and their microenvironment and discuss approaches to inhibit these signalling mechanisms, in particular in the context of cancer immunotherapy. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 24, 2020 Category: Cancer & Oncology Authors: Rik Derynck Shannon J. Turley Rosemary J. Akhurst Source Type: research

SABR for metastasis-directed therapy — what we’ve learned and what’s to come
Nature Reviews Clinical Oncology, Published online: 22 July 2020; doi:10.1038/s41571-020-0416-9SABR-COMET was the first randomized controlled trial to demonstrate an overall survival benefit with the use of stereotactic ablative body radiotherapy (SABR) for the treatment of oligometastatic cancer. Considering the recently reported long-term follow-up data from SABR-COMET, we review the outcomes and limitations of this study in the context of other emerging information on therapy for oligometastatic disease. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 22, 2020 Category: Cancer & Oncology Authors: Tyler P. Robin Jeffrey R. Olsen Source Type: research

Clinical development and potential of photothermal and photodynamic therapies for cancer
Nature Reviews Clinical Oncology, Published online: 22 July 2020; doi:10.1038/s41571-020-0410-2Photodynamic and photothermal therapies hold promise in the local treatment of cancer although, arguably, their full potential has not yet been achieved. Herein, the authors review the current clinical progress of these phototherapies and discuss the bioengineering approaches that are being explored to overcome challenges and thereby improve such treatments. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 22, 2020 Category: Cancer & Oncology Authors: Xingshu Li Jonathan F. Lovell Juyoung Yoon Xiaoyuan Chen Source Type: research

Integrating evolutionary dynamics into cancer therapy
Nature Reviews Clinical Oncology, Published online: 22 July 2020; doi:10.1038/s41571-020-0411-1Most systemic cancer therapies are administered at doses at or close to the maximum tolerated dose until disease progression. However, this approach usually leads to treatment resistance and fails to take into account several potentially relevant evolutionary principles. In this Review, the authors describe how existing approaches to cancer therapy might be optimized by incorporating an understanding of evolutionary dynamics into cancer therapy. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 22, 2020 Category: Cancer & Oncology Authors: Robert A. Gatenby Joel S. Brown Source Type: research

Publisher Correction: The adenosine pathway in immuno-oncology
Nature Reviews Clinical Oncology, Published online: 17 July 2020; doi:10.1038/s41571-020-0415-xPublisher Correction: The adenosine pathway in immuno-oncology (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 17, 2020 Category: Cancer & Oncology Authors: Bertrand Allard David Allard Laurence Buisseret John Stagg Source Type: research

Simultaneous development of zanubrutinib in the USA and China
Nature Reviews Clinical Oncology, Published online: 10 July 2020; doi:10.1038/s41571-020-0414-yZanubrutinib was recently granted expedited approval by the USA and Chinese drug regulatory authorities for the treatment of mantle cell lymphoma, thus becoming the first investigational new drug discovered in China to achieve simultaneous development in both countries. Here, we provide an overview of the regulatory processes and considerations of the two health authorities and discuss the pathways of concurrent review and approval. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 10, 2020 Category: Cancer & Oncology Authors: Guanqiao Li Xiaozhen Liu Xiaoyuan Chen Source Type: research

Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Nature Reviews Clinical Oncology, Published online: 07 July 2020; doi:10.1038/s41571-020-0399-6The availability and subsequent successes of immune-checkpoint inhibitors (ICIs) in patients with metastatic melanoma, and to a lesser extent in those with several other forms of cancer, have made long-term treatment-free remissions a realistic possibility for a subset of patients. In this Perspective, the authors describe available data on long-term remission from patients with melanoma and other solid tumours and provide early recommendations regarding the circumstances in which ICIs can be safely discontinued. (Source: Nature ...
Source: Nature Reviews Clinical Oncology - July 7, 2020 Category: Cancer & Oncology Authors: Caroline Robert Aurelien Marabelle Hugo Herrscher Caroline Caramella Pascal Rouby Karim Fizazi Benjamin Besse Source Type: research

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
Nature Reviews Clinical Oncology, Published online: 06 July 2020; doi:10.1038/s41571-020-0392-0The analysis of ctDNA obtained from low-volume blood samples has the potential to transform the management of patients with colorectal cancer. Nevertheless, research priorities and minimum standards for sample collection and analysis in this area are currently missing. In this Position Paper, the NCI Colon and Rectal–Anal Task Forces provide a set of recommendations designed to address these challenges and accelerate the implementation of ctDNA in the management of patients with colorectal cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 6, 2020 Category: Cancer & Oncology Authors: Arvind Dasari Van K. Morris Carmen J. Allegra Chloe Atreya Al B. Benson III Patrick Boland Ki Chung Mehmet S. Copur Ryan B. Corcoran Dustin A. Deming Andrea Dwyer Maximilian Diehn Cathy Eng Thomas J. George Marc J. Gollub Rachel A. Goodwin Stanley R. Hami Source Type: research

Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Nature Reviews Clinical Oncology, Published online: 29 June 2020; doi:10.1038/s41571-020-0412-0Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 29, 2020 Category: Cancer & Oncology Authors: Nora Pashayan Antonis C. Antoniou Urska Ivanus Laura J. Esserman Douglas F. Easton David French Gaby Sroczynski Per Hall Jack Cuzick D. Gareth Evans Jacques Simard Montserrat Garcia-Closas Rita Schmutzler Odette Wegwarth Paul Pharoah Sowmiya Moorthie Sand Source Type: research

Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Nature Reviews Clinical Oncology, Published online: 22 June 2020; doi:10.1038/s41571-020-0387-xImmune-checkpoint inhibition has transformed the treatment of patients with advanced-stage cancers. Nonetheless, the specific antigens targeted by T cells that are activated or reactivated by these agents remain largely unknown. In this Review, the authors describe the characterization and classification of tumour antigens including descriptions of the most appropriate detection methods, and discuss potential regulatory issues regarding the use of tumour antigen-based therapeutics. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 22, 2020 Category: Cancer & Oncology Authors: Sebastian P. Haen Markus W. L öffler Hans-Georg Rammensee Peter Brossart Source Type: research

Rituximab for paediatric NHL
Nature Reviews Clinical Oncology, Published online: 19 June 2020; doi:10.1038/s41571-020-0409-8Rituximab for paediatric NHL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 19, 2020 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

ICI rechallenge in mRCC
Nature Reviews Clinical Oncology, Published online: 19 June 2020; doi:10.1038/s41571-020-0407-xICI rechallenge in mRCC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 19, 2020 Category: Cancer & Oncology Authors: David Killock Source Type: research

Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Nature Reviews Clinical Oncology, Published online: 18 June 2020; doi:10.1038/s41571-020-0388-9Risk-adapted approaches to breast cancer prevention and screening could potentially be more effective than universal approaches, which have important limitations. In this Consensus Statement, representatives of the European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. They also present the ENVISION recommendations on priorities for future resea...
Source: Nature Reviews Clinical Oncology - June 18, 2020 Category: Cancer & Oncology Authors: Nora Pashayan Antonis C. Antoniou Urska Ivanus Laura J. Esserman Douglas F. Easton David French Gaby Sroczynski Per Hall Jack Cuzick D. Gareth Evans Jacques Simard Montserrat Garcia-Closas Rita Schmutzler Odette Wegwarth Paul Pharoah Sowmiya Moorthie Sand Source Type: research

Towards multi-cancer screening using liquid biopsies
Nature Reviews Clinical Oncology, Published online: 17 June 2020; doi:10.1038/s41571-020-0404-0Cell-free DNA and proteins are secreted into the bloodstream by multiple types of cancer. In a recently published prospective study involving 10,006 women, such markers were used in a cancer screening approach that incorporated PET–CT as a confirmatory test. Herein, we discuss the implications of these results. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 17, 2020 Category: Cancer & Oncology Authors: Y. M. Dennis Lo W. K. Jacky Lam Source Type: research

Reply to ‘Personalized treatment of immune-related adverse events — balance is required’
Nature Reviews Clinical Oncology, Published online: 16 June 2020; doi:10.1038/s41571-020-0401-3Reply to ‘Personalized treatment of immune-related adverse events — balance is required’ (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 16, 2020 Category: Cancer & Oncology Authors: Kashayar Esfahani Leonard Calabrese Source Type: research

Personalized treatment of immune-related adverse events — balance is required
Nature Reviews Clinical Oncology, Published online: 16 June 2020; doi:10.1038/s41571-020-0400-4Personalized treatment of immune-related adverse events — balance is required (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 16, 2020 Category: Cancer & Oncology Authors: Filipe Martins Michel Obeid Source Type: research

Lung cancer at ASCO20 Virtual
Nature Reviews Clinical Oncology, Published online: 12 June 2020; doi:10.1038/s41571-020-0405-zLung cancer at ASCO20 Virtual (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 12, 2020 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Trastuzumab deruxtecan improves survival
Nature Reviews Clinical Oncology, Published online: 12 June 2020; doi:10.1038/s41571-020-0406-yTrastuzumab deruxtecan improves survival (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 12, 2020 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Histology-agnostic drug development — considering issues beyond the tissue
Nature Reviews Clinical Oncology, Published online: 11 June 2020; doi:10.1038/s41571-020-0384-0Therapies are being developed to treat cancers on the basis of specific molecular alterations and markers of immune phenotypes that transcend specific tumour histologies. The authors summarize the development and testing of approved histology-agnostic therapeutic agents, present data on other agents under development and discuss the challenges intrinsic to histology-agnostic drug development in oncology, including biological, regulatory, design and statistical considerations. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 11, 2020 Category: Cancer & Oncology Authors: Roberto Carmagnani Pestana Shiraj Sen Brian P. Hobbs David S. Hong Source Type: research

Atezolizumab improves outcomes in mUC
Nature Reviews Clinical Oncology, Published online: 11 June 2020; doi:10.1038/s41571-020-0398-7Atezolizumab improves outcomes in mUC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 11, 2020 Category: Cancer & Oncology Authors: Linda Gummlich Source Type: research

From the ASCO20 Virtual meeting
Nature Reviews Clinical Oncology, Published online: 09 June 2020; doi:10.1038/s41571-020-0402-2From the ASCO20 Virtual meeting (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 9, 2020 Category: Cancer & Oncology Authors: David Killock Source Type: research

The adenosine pathway in immuno-oncology
Nature Reviews Clinical Oncology, Published online: 08 June 2020; doi:10.1038/s41571-020-0382-2Signalling induced by extracellular adenosine (eADO) can suppress antitumour immunity through multiple mechanisms. Herein, the authors review the pathophysiological functions of eADO in cancer and the related prognostic implications. They discuss the associated opportunities for eADO pathway-targeted immunotherapy, highlighting potential limitations and the scope for combination and biomarker-based strategies. The data emerging from oncology clinical trials of the diverse range of therapies that have been developed to target the ...
Source: Nature Reviews Clinical Oncology - June 8, 2020 Category: Cancer & Oncology Authors: Bertrand Allard David Allard Laurence Buisseret John Stagg Source Type: research

MET-dependent solid tumours — molecular diagnosis and targeted therapy
Nature Reviews Clinical Oncology, Published online: 08 June 2020; doi:10.1038/s41571-020-0377-zTherapies targeting MET-overexpressing cancers have limited efficacy. However, owing to advances in detection methods, therapies targeting MET-dependent tumours harbouring MET amplifications, activating mutations or fusions are emerging. In this review, the authors describe emerging data on this new class of targeted therapies. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 8, 2020 Category: Cancer & Oncology Authors: Robin Guo Jia Luo Jason Chang Natasha Rekhtman Maria Arcila Alexander Drilon Source Type: research

ICI for resected stage IV melanoma
Nature Reviews Clinical Oncology, Published online: 29 May 2020; doi:10.1038/s41571-020-0397-8ICI for resected stage IV melanoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 29, 2020 Category: Cancer & Oncology Authors: David Killock Source Type: research

The changing landscape of cancer in the USA — opportunities for advancing prevention and treatment
Nature Reviews Clinical Oncology, Published online: 28 May 2020; doi:10.1038/s41571-020-0378-yMonitoring both cancer incidence and death rates is important for guiding health policy and the direction of future research. In this Perspective, the authors describe changes in cancer incidence and death rates in the USA, highlighting the effects of specific policies and research developments, and providing insight into unmet needs that should be addressed by future health policies. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 28, 2020 Category: Cancer & Oncology Authors: Farhad Islami Rebecca L. Siegel Ahmedin Jemal Source Type: research

Liquid biopsy for early stage lung cancer moves ever closer
Nature Reviews Clinical Oncology, Published online: 26 May 2020; doi:10.1038/s41571-020-0393-zLung cancer screening is currently based only on low-dose CT scans; however, novel, more accessible methods that might improve uptake and adherence are eagerly awaited. New liquid biopsy approaches promise to revolutionize cancer screening. Herein, we discuss the opportunities and challenges associated with two such novel assays. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 26, 2020 Category: Cancer & Oncology Authors: Christian Rolfo Alessandro Russo Source Type: research

Combination set to transform HCC therapy
Nature Reviews Clinical Oncology, Published online: 26 May 2020; doi:10.1038/s41571-020-0396-9Combination set to transform HCC therapy (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 26, 2020 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one?
Nature Reviews Clinical Oncology, Published online: 23 May 2020; doi:10.1038/s41571-020-0395-xMature results of the PROfound study demonstrate that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib prolongs progression-free survival compared with second-generation hormonal therapies in men with metastatic castration-resistant prostate cancer harbouring BRCA1, BRCA2 or ATM mutations. However, a closer look at the efficacy of olaparib on a gene-by-gene basis suggests that its activity is most pronounced in BRCA2-mutant prostate cancers and might not be equally active in all homologous recombination repair-deficient c...
Source: Nature Reviews Clinical Oncology - May 23, 2020 Category: Cancer & Oncology Authors: Emmanuel S. Antonarakis Source Type: research

Microbial DNA signature in plasma enables cancer diagnosis
Nature Reviews Clinical Oncology, Published online: 18 May 2020; doi:10.1038/s41571-020-0391-1Bacteria within tumours affect progression and response to therapy; in addition, bacterial DNA can be detected in cell-free plasma. Herein, we discuss evidence showing that intratumoural bacteria are characteristic for each tumour type, and that detection of cell-free bacterial DNA in blood could provide an accurate and non-invasive test for cancer diagnosis. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 18, 2020 Category: Cancer & Oncology Authors: Amiran Dzutsev Giorgio Trinchieri Source Type: research

COVID-19 and cancer: do we really know what we think we know?
Nature Reviews Clinical Oncology, Published online: 18 May 2020; doi:10.1038/s41571-020-0394-yEarly published data on COVID-19 in patients with cancer are being referenced in clinical guidelines, despite methodological flaws that limit the quality of much of this evidence. In the next phase of research in this area, we argue that the quality of observational evidence should be prioritized over speed of publication. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 18, 2020 Category: Cancer & Oncology Authors: Andrew G. Robinson Bishal Gyawali Gerald Evans Source Type: research

From AACR 2020 (part 1)
Nature Reviews Clinical Oncology, Published online: 13 May 2020; doi:10.1038/s41571-020-0386-yFrom AACR 2020 (part 1) (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 13, 2020 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

COVID-19: more evidence emerges
Nature Reviews Clinical Oncology, Published online: 12 May 2020; doi:10.1038/s41571-020-0390-2COVID-19: more evidence emerges (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 12, 2020 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Activity of regorafenib plus nivolumab
Nature Reviews Clinical Oncology, Published online: 12 May 2020; doi:10.1038/s41571-020-0389-8Activity of regorafenib plus nivolumab (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 12, 2020 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Nature Reviews Clinical Oncology, Published online: 12 May 2020; doi:10.1038/s41571-020-0363-5Important research efforts are being made to develop therapeutic strategies targeting the tumour microenvironment in pancreatic adenocarcinoma. The authors of this Review describe the apparent contradiction between preclinical studies and clinical outcomes observed to date, presenting more sophisticated strategies under active investigation. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 12, 2020 Category: Cancer & Oncology Authors: Won Jin Ho Elizabeth M. Jaffee Lei Zheng Source Type: research

REACH2: ruxolitinib for refractory aGvHD
Nature Reviews Clinical Oncology, Published online: 06 May 2020; doi:10.1038/s41571-020-0385-zREACH2: ruxolitinib for refractory aGvHD (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 6, 2020 Category: Cancer & Oncology Authors: David Killock Source Type: research

Treatment-free remission in patients with chronic myeloid leukaemia
Nature Reviews Clinical Oncology, Published online: 06 May 2020; doi:10.1038/s41571-020-0367-1International treatment guidelines for chronic myeloid leukaemia incorporate recommendations for attempting discontinuation of treatment with tyrosine-kinase inhibitors (TKIs) with the aim of a treatment-free remission (TFR). The authors of this Review discuss how results of clinical studies of TFR can guide routine practice, address the development of predictors of outcome after TKI discontinuation and present strategies that warrant further consideration to enable more patients to enter TFR. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 6, 2020 Category: Cancer & Oncology Authors: David M. Ross Timothy P. Hughes Source Type: research

Avoiding collateral mortality in a pandemic — time to change our mindset in surgical oncology
Nature Reviews Clinical Oncology, Published online: 05 May 2020; doi:10.1038/s41571-020-0383-1The coronavirus disease 19 (COVID-19) pandemic has become the focus of attention worldwide, and herein we seek to highlight the potential problem of ‘collateral mortality’ from delayed or deferred treatments in patients with cancer. We propose potential solutions to ensure continuity of care in the field of surgical oncology. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 5, 2020 Category: Cancer & Oncology Authors: Ker-Kan Tan Brendan J. Moran Michael J. Solomon Source Type: research

B cells and complement at the forefront of chemotherapy
Nature Reviews Clinical Oncology, Published online: 05 May 2020; doi:10.1038/s41571-020-0376-0Effective anticancer therapies typically activate antitumour immunity, predominately mediated by T cells in the tumour microenvironment. Here, we discuss the roles of B cells and tertiary lymphoid structures in the context of chemotherapy-induced complement activation, which results in the induction of a B cell subset that modulates T cell function. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 5, 2020 Category: Cancer & Oncology Authors: Catherine Saut ès-Fridman Lubka T. Roumenina Source Type: research

Acalabrutinib — a new option in CLL
Nature Reviews Clinical Oncology, Published online: 01 May 2020; doi:10.1038/s41571-020-0381-3Acalabrutinib — a new option in CLL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 1, 2020 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Anti-CD22 CAR T cells in ALL
Nature Reviews Clinical Oncology, Published online: 01 May 2020; doi:10.1038/s41571-020-0379-xAnti-CD22 CAR T cells in ALL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 1, 2020 Category: Cancer & Oncology Authors: David Killock Source Type: research

Palliative care services at cancer centres — room for improvement
Nature Reviews Clinical Oncology, Published online: 30 April 2020; doi:10.1038/s41571-020-0374-2Evidence of quality of life improvements in patients with advanced-stage cancer has spurred a move towards early integration of palliative care into the outpatient setting. As discussed herein, meaningful and sustained improvements in timely access to palliative care requires commitments to funding, encouraging integration and routinizing referral across care settings. More palliative medicine training positions as well as broader education of clinicians and the public about the benefits of palliative care throughout the disease...
Source: Nature Reviews Clinical Oncology - April 30, 2020 Category: Cancer & Oncology Authors: Jean Mathews Camilla Zimmermann Source Type: research

Low-grade glioma subtypes revealed
Nature Reviews Clinical Oncology, Published online: 30 April 2020; doi:10.1038/s41571-020-0380-4Low-grade glioma subtypes revealed (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 30, 2020 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Progress in refining the clinical management of cancer of unknown primary in the molecular era
Nature Reviews Clinical Oncology, Published online: 29 April 2020; doi:10.1038/s41571-020-0359-1Despite improvements in diagnostic strategies, cancer of unknown primary — metastatic cancer in patients in whom the primary tumour remains undetected — continues to account for around 1–2% of all cancers. In this Review, Rassy and Pavlidis discuss insights into the biology of CUP and shifts in the clinical management of this enigmatic disease entity in the era of precision medicine. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 29, 2020 Category: Cancer & Oncology Authors: Elie Rassy Nicholas Pavlidis Source Type: research